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Statement of findings
CD8+ T cells dominate the lymphocyte population in synovial fluid in chronic inflammatory
arthritis. It is known that these CD8+ T cells are often clonally or oligoclonally expanded, but
their specificity and their relevance to the pathogenesis of joint disease has remained
unclear. We found that as many as 15.5% of synovial CD8+ T cells may be specific for a
single epitope from an Epstein–Barr virus lytic cycle protein. The virus-specific T cells within
the joint showed increased expression of markers of activation and differentiation compared
with those in the periphery, and retained their functional capacity to secrete proinflammatory
cytokines on stimulation. These activated, virus-specific CD8+ T cells could therefore
interact with synoviocytes, either by cell–cell contact or by a cytokine network, and play a
‘bystander’ role in the maintenance of inflammation in patients with arthritis.
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Introduction: Epstein–Barr virus (EBV) is transmitted orally,
replicates in the oropharynx and establishes life-long latency
in human B lymphocytes. T-cell responses to latent and
lytic/replicative cycle proteins are readily detectable in
peripheral blood from healthy EBV-seropositive individuals.
EBV has also been detected within synovial tissue, and T-
cell responses to EBV lytic proteins have been reported in
synovial fluid from a patient with rheumatoid arthritis (RA).
This raises the question regarding whether T cells specific
for certain viruses might be present at high frequencies
within synovial fluid and whether such T cells might be
activated or able to secrete cytokines. If so, they might play a
‘bystander’ role in the pathogenesis of inflammatory joint
disease.
Objectives: To quantify and characterize T cells that are
specific for epitopes from EBV, cytomegalovirus (CMV) and
influenza in peripheral blood and synovial fluid from patients
with arthritis.
http://arthritis-research.com/content/2/2/154http://arthritis-research.com/content/2/2/154
Methods: Peripheral blood mononuclear cells (PBMCs) and
synovial fluid mononuclear cells (SFMCs) were obtained from
patients with inflammatory arthritis (including those with RA,
osteoarthritis, psoriatic arthritis and reactive arthritis). Samples
from human leucocyte antigen (HLA)-A2-positive donors were
stained with fluorescent-labelled tetramers of HLA-A2
complexed with the GLCTLVAML peptide epitope from the EBV
lytic cycle protein BMLF1, the GILGFVFTL peptide epitope from
the influenza A matrix protein, or the NLVPMVATV epitope from
the CMV pp65 protein. Samples from HLA-B8-positive donors
were stained with fluorescent-labelled tetramers of HLA-B8
complexed with the RAKFKQLL peptide epitope from the EBV
lytic protein BZLF1 or the FLRGRAYGL peptide epitope from
the EBV latent protein EBNA3A. All samples were costained
with an antibody specific for CD8. CD4+ T cells were not
analyzed. Selected samples were costained with antibodies
specific for cell-surface glycoproteins, in order to determine the
phenotype of the T cells within the joint and the periphery.
Functional assays to detect release of IFN-g or tumour necrosis
factor (TNF)-a were also performed on some samples.
Results: The first group of 15 patients included 10 patients
with RA, one patient with reactive arthritis, one patient with
psoriatic arthritis and three patients with osteoarthritis. Of
these, 11 were HLA-A2 positive and five were HLA-B8
positive. We used HLA–peptide tetrameric complexes to
analyze the frequency of EBV-specific T cells in PBMCs and
SFMCs (Figs 1 and 2). Clear enrichment of CD8+ T cells
specific for epitopes from the EBV lytic cycle proteins was
seen within synovial fluid from almost all donors studied,
including patients with psoriatic arthritis and osteoarthritis and
those with RA. In donor RhA6, 9.5% of CD8+ SFMCs were
specific for the HLA-A2 restricted GLCTLVAML epitope,
compared with 0.5% of CD8+ PBMCs. Likewise in a donor
with osteoarthritis (NR4), 15.5% of CD8+ SFMCs were
specific for the HLA-B8-restricted RAKFKQLL epitope,
compared with 0.4% of CD8+ PBMCs. In contrast, we did not
find enrichment of T cells specific for the HLA-B8-restricted
FLRGRAYGL epitope (from the latent protein EBNA3A) within
SFMCs compared with PBMCs in any donors. In selected
individuals we performed ELISpot assays to detect IFN-g
secreted by SFMCs and PBMCs after a short incubation in
vitro with peptide epitopes from EBV lytic proteins. These
assays confirmed enrichment of T cells specific for epitopes
from EBV lytic proteins within synovial fluid and showed that
subpopulations of these cells were able to secrete
proinflammatory cytokines after short-term stimulation.
We used a HLA-A2/GILGFVFTL tetramer to stain PBMCs and
SFMCs from six HLA-A2-positive patients. The proportion of T
cells specific for this influenza epitope was low (<0.2%) in all
donors studied, and we did not find any enrichment within
SFMCs.
We had access to SFMCs only from a second group of four HLA-
A2-positive patients with RA. A tetramer of HLA-A2 complexed to
the NLVPMVATV epitope from the CMV pp65 protein reacted
with subpopulations of CD8+ SFMCs in all four donors, with
frequencies of 0.2, 0.5, 2.3 and 13.9%. SFMCs from all four
donors secreted TNF after short-term incubation with COS cells
transfected with HLA-A2 and pp65 complementary DNA.
We analyzed the phenotype of virus-specific cells within
PBMCs and SFMCs in three donors. The SFMC virus-specific
T cells were more highly activated than those in PBMCs, as
evidenced by expression of high levels of CD69 and HLA-DR.
A greater proportion of SFMCs were CD38+, CD62L low,
CD45RO bright, CD45RA dim, CD57+ and CD28– when
compared with PBMCs.
Discussion: This work shows that T cells specific for certain
epitopes from viral proteins are present at very high frequencies
(up to 15.5% of CD8+ T cells) within SFMCs taken from
patients with inflammatory joint disease. This enrichment does
not reflect a generalized enrichment for the ‘memory pool’ of T
cells; we did not find enrichment of T cells specific for the
Figure 1
Staining of paired samples of peripheral blood and synovial fluid with
human leucocyte antigen (HLA)–peptide tetrameric complexes. Paired
samples of peripheral blood mononuclear cells (PBMCs; left column)
and synovial fluid mononuclear cells (SFMCs; right column) from
donors (a) RhA6, (b, c) RhA5 and (d) RhA7 were stained with a
monoclonal antibody that was specific for CD8 and with (a, b) the
A2/GLCTLVAML tetramer or (c, d) the B8/RAKFKQLL tetramer. The
percentage frequency of CD8+ T cells that reacted with the tetrameric
complexes is shown; 50 000 live cells were included in the analysis.Arthritis Research    Vol 2 No 2 Tan et al
Introduction
Epstein–Barr virus (EBV) is a common gammaherpesvirus
that infects over 90% of individuals worldwide [1]. The
virus is transmitted orally, replicates in the oropharynx and
subsequently establishes life-long latent infection of B lym-
phocytes [2]. Replicative infection is associated with the
expression of approximately 70EBV ‘lytic’ proteins,
whereas latent infection is associated with the expression
of up to nine ‘latent’ proteins [3,4]. The cellular immune
response plays a crucial role in controlling EBV infection.
T-cell responses to EBV latent proteins have been well
studied and are easily detectable in healthy EBV-seroposi-
tive individuals [5–7]. More recently, responses to some of
the EBV lytic cycle proteins have also been described
[7–10]; reactivities to these antigens are frequently found
to be more abundant than those directed against the EBV
latent antigens in healthy EBV carriers [7,9,10].
An association between EBV and rheumatoid arthritis
(RA) was first proposed on the basis of high titres of EBV-
specific antibodies found in some patients with RA
[11,12]. The observation that some of the anti-EBV anti-
bodies were cross-reactive with autoantigens such as col-
lagen was put forward as a further argument in support of
the link [13]. The importance of these findings in the
pathophysiology of rheumatoid arthritis has never been
Full article
GILGFVFTL epitope from influenza A or for the FLRGRAYGL
epitope from the EBV latent protein EBNA3A, whereas we
found clear enrichment of T cells specific for the GLCTLVAML
epitope from the EBV lytic protein BMLF1 and for the
RAKFKQLL epitope from the EBV lytic protein BZLF1.
The enrichment might reflect preferential recruitment of
subpopulations of virus-specific T cells, perhaps based on
expression of selectins, chemokine receptors or integrins.
Alternatively, T cells specific for certain viral epitopes may be
stimulated to proliferate within the joint, by viral antigens
themselves or by cross-reactive self-antigens. Finally, it is
theoretically possible that subpopulations of T cells within the
joint are preferentially protected from apoptotic cell death.
Whatever the explanation, the virus-specific T cells are present
at high frequency, are activated and are able to secrete
proinflammatory cytokines. They could potentially interact with
synoviocytes and contribute to the maintenance of inflammation
within joints in many different forms of inflammatory arthritis.
Figure 2
T cells specific for the Epstein–Barr virus (EBV) lytic protein epitopes GLCTLVAML and RAKFKQLL are enriched within synovial fluid. Paired
samples of peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were stained with (a) the A2/GLCTLVAML
tetramer or (b) the B8/RAKFKQLL tetramer together with a monoclonal antibodies specific for CD8. The percentage of CD8+ T cells that react
with the relevant tetrameric complex is shown. L, left knee; R, right knee.
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(a) (b)established, however. More recently the cloning of T cells
that are specific for EBV antigens from synovial fluid taken
from a patient with RA [14] has reopened the debate
regarding the importance of this virus in the aetiology of
arthritis. David-Ameline et al [15] showed that a large pro-
portion of T-cell clones derived from synovial fluid taken
from one individual with RA, under polyclonal activation
conditions, recognized EBV-transformed lymphoblastoid
cell lines in an human leucocyte antigen (HLA)-restricted
manner. Subsequent work revealed that these T-cell
clones recognized epitopes from EBV lytic cycle proteins
[14]. Analysis of the T-cell receptor use of the EBV-spe-
cific T cell clones and of the T-cell receptor repertoire of
synovial fluid lymphocytes [14,15] suggested that the
EBV-specific T cells were clonally expanded within the
synovial fluid from this donor. In some other donors, short-
term T-cell lines derived from synovial fluid lymphocytes,
but not those derived from peripheral blood lymphocytes,
secreted low levels of tumour necrosis factor (TNF) in
response to stimulation with an EBV antigen [14,16].
These results suggested that EBV-specific T cells might
form a component of joint infiltrating lymphocytes in
patients with RA.
In the present study we used tetrameric HLA–peptide
complexes [17] to investigate the T-cell response to EBV,
cytomegalovirus (CMV) and influenza in individuals with
inflammatory arthritis. We made tetramers of HLA mole-
cules complexed to peptide epitopes from EBV latent and
lytic proteins [7,10], to an epitope from a CMV structural
protein [18] and to an epitope from influenza A matrix
protein [19]. We used these tetramers to quantify and
characterize virus-specific CD8+ T cells within samples of
peripheral blood and synovial fluid taken from patients with
inflammatory arthritis. The experiments show that CD8+ T
cells specific for certain viral antigens are enriched within
synovial fluid. The enrichment could reflect recruitment
into, stimulation within or preferential survival within
inflamed joints. The virus-specific T cells are activated and
subpopulations are able to secrete proinflammatory
cytokines. These T cells could therefore interact with syn-
oviocytes and play a role in the maintenance of inflamma-
tion in chronic arthritis.
Materials and methods
Patient samples
Samples of synovial fluid and peripheral venous blood
were initially obtained from a group of 15 EBV-seroposi-
tive patients, 13 of whom were HLA-A2 positive and/or
HLA-B8 positive. Ten patients (RhA1–RhA10) suffered
from RA, one from reactive arthritis (NR1), one from psori-
atic arthritis (NR2) and three from osteoarthritis
(NR3–NR5). Details of these patients are given in Table 1.
Peripheral blood mononuclear cells (PBMCs) and synovial
fluid mononuclear cells (SFMCs) were isolated using
Lymphoprep (Nycomed Pharma, Oslo, Norway) gradient
centrifugation and cryopreserved in 10% dimethyl
sulphoxide, 90% fetal calf syndrome at –70°C. Only syn-
ovial lymphocytes were available for analysis from a
smaller second group of HLA-A2-positive RA patients
(RA3, RA11, RA14 and RA15), whose clinical status has
been described elsewhere [16].
Human leucocyte antigen typing
Genomic DNA was extracted from whole blood using a
Puregene kit (Gentra systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions. Each patient
was tissue typed using polymerase chain reaction, as pre-
viously described [20]. HLA-A and HLA-B types are sum-
marized in Table 1.
Tetrameric class I human leucocyte antigen–peptide
complexes. 
HLA–peptide tetramers were produced as previously
described [7,10]. Briefly, recombinant class I heavy chain
or b2-microglobulin was produced in Escherichia coli cells
transformed with the relevant expression plasmids.
Expression of the heavy chain was limited to the extracellu-
lar domain and the sequence of this domain was modified
http://arthritis-research.com/content/2/2/154
Table 1
Patient details
Patients HLA-A HLA-B Diagnosis
Group 1 RhA1 2, 29 44, 49 Rheumatoid arthritis 
RhA2 2, 29 39, 44 Rheumatoid arthritis
RhA3 2, 3 7, 62 Rheumatoid arthritis
RhA4 2, 31 7, 8 Rheumatoid arthritis
RhA5 1, 2 8, 62 Rheumatoid arthritis
RhA6 2 – Rheumatoid  arthritis
RhA7 1, 29 8, 44 Rheumatoid arthritis
RhA8 2, 30 44, 52 Rheumatoid arthritis
RhA9 2, 3 7, 35  Rheumatoid arthritis
RhA10 29, 32 40, 44 Rheumatoid arthritis
NR1 1,2 27,49 Reactive arthritis
NR2 2, 36 8, 60 Psoriatic arthritis
NR3 1, 2 7, 62 Osteoarthritis
NR4 1, 31 40, 52 Osteoarthritis
NR5 – 8 Osteoarthritis
Group 2 RA3 1, 2 8, 44 Rheumatoid arthritis 
RA11 2 27, 44 Rheumatoid arthritis 
RA14 2 15, 44 Rheumatoid arthritis 
RA15 2, 11 8, 27 Rheumatoid arthritis 
The HLA-B type of patient RhA6 and the HLA-A type of patient NR5
were not determined.Arthritis Research    Vol 2 No 2 Tan et al
by the addition of a substrate sequence for BirA biotinyla-
tion at the carboxyl terminus. The HLA–peptide complexes
were folded in vitro using 30mg heavy chain, 25mg
b2-microglobulin and 10mg peptide, then biotinylated
using purified BirA enzyme (Avidity, Denvery, CO, USA).
The biotinylated complexes were recovered by fast perfor-
mance liquid chromatography (FPLC) purification and ion
exchange chromatography. Tetramers were made by
mixing biotinylated protein complex with streptavidin-phy-
coerythrin (PE) at a molar ratio of 4:1. The three HLA-A2
tetrameric complexes synthesized for this study contained
either the influenza A virus matrix peptide GILGFVFTL [19]
(A2/FluM tetramer), the EBV BMLF1 peptide GLCTL-
VAML [9,14] (A2/GLC tetramer), or the CMV pp65
peptide NLVPMVATV [18] (A2/NLV tetramer). Two HLA-
B8 tetramers were also made, with the EBV EBNA3A
peptide FLRGRAYGL [21] (B8/FLR tetramer), or the EBV
BZLF1 peptide RAKFKQLL [8,9] (B8/RAK tetramer).
ELISpot assay for IFN-g g release by stimulated T cells
This assay was used to detect IFN-g production by T cells
in fresh samples of PBMCs and SFMCs on antigen stimu-
lation. Ninety-six-well polyvinylidene difluoride backed
plates (Millipore, Watford, UK) were precoated with
15mg/ml of anti-IFN-g monoclonal antibody 1-DIK
(Mabtech, Stockholm, Sweden). PBMCs were added in
duplicate wells at 2.5×105, 1.25×105 and 6.25×104
cells/well and incubated overnight at 37°C, 5% carbon
dioxide with the exact 8-mer or 9-mer peptide antigen
(2mmol/l final concentration). The cells were discarded the
following day and the second biotinylated anti-IFN-g mono-
clonal antibody, 7-B6-1 biotin (Mabtech, Stockholm,
Sweden), was added at 1mg/ml and left for 3h at room
temperature, followed by streptavidin-conjugated alkaline
phosphatase (Mabtech, Stockholm, Sweden) for a further
2h. Individual cytokine-producing cells were detected as
dark spots after a 30-min reaction with 5-bromo-4-chloro-
3-indolyl phosphate and nitroblue tetrazolium using a pre-
mixed alkaline phosphatase conjugate substrate kit
(Bio-Rad, Richmond, CA, USA). The spots were counted
under a dissection microscope. The number of specific
responders was calculated after subtracting negative
control values.
COS transfections and T cell stimulation assay
COS cells were transfected with HLA-A2 and pp65 com-
plementary DNA as previously described [16]. CD8+
SFMCs (104 and 105) were incubated with the trans-
fected COS cells for 6h. The culture supernatant was har-
vested and tested for TNF-a content by measuring culture
supernatant cytotoxicity against Wehi 164 clone 13 in a
colorimetric assay as previously described [16].
Cell staining and flow cytometry
PBMCs were incubated for 30min in phosphate-buffered
saline with 0.16% bovine serum albumin and 0.1%
sodium azide, containing 0.5mg/ml phycoerythrin-labelled
tetrameric complex, washed and then stained on ice with
saturating amounts of an anti-CD8 monoclonal antibody
directly conjugated to Tricolor (Caltag Laboratories, San
Francisco, CA, USA). For phenotypic analysis, selected
samples were also incubated with one of a panel of mono-
clonal antibodies directed against cell-surface markers.
This panel consisted of anti-CD28 fluorescein isothio-
cyanate (FITC) (Immunotech, Marseilles, France), anti-
CD45RA FITC (Immunotech, Marseilles, France),
anti-CD45RO FITC (DAKO, Glostrup, Denmark), anti-
CD57 FITC (Becton-Dickinson, Mountain View, CA, USA),
anti-CD62L FITC (Pharmingen, San Diego, CA, USA),
anti-CD69 FITC (DAKO) and anti-HLA DR FITC (DAKO).
All samples were fixed in 2% formaldehyde and analyzed
using a fluorescent antibody cell sorter using CELLQuest
software (Becton-Dickinson). For two-colour analysis
50000 live cells were analyzed. For three-colour analysis
200000 live cells were analyzed. In each experiment the
lymphocyte pool was identified using forward and side
scatter analysis and markers were set to analyze the CD8hi
subset of CD3+ T cells. CD4+ T-cell responses were not
analyzed in the present study.
Results
Presence of T cells specific for Epstein–Barr virus in
synovial fluid
In the first group of patients we used HLA–peptide
tetrameric complexes to analyze the frequency of CD8+ T
cells specific for two EBV lytic protein epitopes, the
HLA-A2 restricted epitope (GLCTLVAML) from BMLF1
[9,14] and the HLA-B8 restricted epitope (RAKFKQLL)
from BZLF1 [8,9], and for an EBV latent protein epitope,
the HLA-B8 restricted epitope (FLRGRAYGL) from
EBNA3A [21].
We initially studied 11 HLA-A2+ patients with inflammatory
arthritis. In patient RhA6, 9.5% of CD8+ T cells within syn-
ovial fluid were specific for the GLCTLVAML epitope from
BMLF1, whereas only 0.5% CD8+ T cells within peripheral
blood were specific for this epitope (Figs 1a and 2a). Like-
wise in patient RhA5, T cells that were specific for the
GLCTLVAML epitope were clearly enriched within synovial
fluid (4.5% of CD8+ T cells) when compared with periph-
eral blood (1.0%; Figs 1b and 2a). In four of the six other
HLA-A2+ individuals with RA (RhA2, RhA3, RhA8, RhA9),
we also found higher frequencies of T cells specific for
GLCTLVAML in synovial fluid than in peripheral blood
(Fig. 2a). This finding was not restricted to patients with
RA; we found enrichment of GLCTLVAML-specific T cells
in synovial fluid taken from patients with psoriatic arthritis
(NR2) and osteoarthritis (NR3; Fig. 2a).
We identified five HLA-B8+ patients, three of whom suf-
fered from RA (RhA4, RhA5, RhA7), one of whom hadpsoriatic arthritis (NR2) and one of whom had osteoarthri-
tis (NR5). In patient RhA5, 13.1% CD8+ T cells within
synovial fluid reacted with the B8–RAK tetrameric
complex compared with 4.3% within peripheral blood
(Figs 1c and 2b). Similarly in patient RhA7, we found that
7.3% of CD8+ T cells were specific for the RAKFKQLL
epitope in synovial fluid compared with 0.9% CD8+ T cells
within the periphery (Figs 1d and 2b). In the third RA
patient, as well as in patients with psoriatic arthritis and
osteoarthritis, the frequencies of T cells specific for the
RAKFKQLL epitope were also much higher in synovial
fluid than in peripheral blood (Fig. 2b).
T cells that were specific for the HLA-B8 restricted
epitope (FLRGRAYGL) from the EBV latent protein
EBNA3A were either undetectable or present at only very
low frequencies (<0.1% of CD8+ T cells) in three of the
five HLA-B8+ patients studied. In donor RhA7 we found
FLRGRAYGL-specific T cells at a frequency of 0.5%
CD8+ T cells in peripheral blood and 0.4% CD8+ T cells
in synovial fluid. In a patient with osteoarthritis (NR4) we
found FLRGRAYGL-specific T cells at a frequency of
0.4% in peripheral blood and 0.2% in synovial fluid. Thus,
using this technique we did not find evidence for enrich-
ment of T cells specific for this EBV latent epitope within
synovial fluid of patients with inflammatory arthritis.
In general the frequencies of EBV-reactive T cells within
peripheral blood of the patients studied were similar to
those previously reported in healthy individuals [7] using
this technique, despite the use of immunosuppressive
drugs.
In selected individuals we performed ELISpot assays to
detect IFN-g secreted by SFMCs and PBMCs after a short
incubation in vitro with peptide epitopes from EBV lytic
proteins (Fig. 3). We calculated that the estimates of fre-
quency of virus-specific T cells obtained with an ELISpot
assay for IFN-g secretion were a mean of 19.9-fold and
20.1-fold lower than those obtained with tetramer staining
in peripheral blood and synovial fluid, respectively. We
have previously shown that in healthy control individuals
estimates of frequency of EBV-specific T cells obtained
with the ELISpot assay are a mean of 4.4-fold lower than
those obtained by staining with tetrameric complexes [7].
Thus, the ability of the virus-specific T cells to secrete IFN-
g appeared to be impaired both in peripheral blood and
synovial fluid in the present patient group. The correlation
between the numbers of T cells that were detected using
an ELISpot assay versus tetramer staining was relatively
poor in this group of patients, suggesting interindividual
and intersite differences in the functional capacity of the
antigen-specific T cells. Despite these limitations, the
results of the assays showed enrichment for T cells that
were specific for epitopes from EBV lytic proteins within
synovial fluid, and showed that subpopulations of these
cells are able to secrete proinflammatory cytokines after
short-term stimulation.
T cells specific for cytomegalovirus may also be present at
high frequencies within synovial fluid
In light of recent results that suggest increased responses
of synovial lymphocytes from some RA patients to CMV
antigens derived from pp65 and IE1 proteins [16], we also
assessed the number of SFMCs specific for a CMV
epitope in a second group of four patients. HLA-A2
tetramers carrying a CMV-derived epitope (pp65 NLVPM-
VATV) were made and used to stain CD8+ synovial fluid
lymphocytes from four HLA-A2+ RA patients (RA3, RA11,
RA14 and RA15). Paired samples of peripheral blood
from these donors were not available for comparative
analysis. The frequency of A2/NLV-reactive cells varied
greatly from one patient to another, but reached up to
13.9% in one patient (RA15; Table 2). Consistent with
these findings, CD8+ SFMCs from these donors secreted
TNF-a after short-term incubation with COS cells trans-
fected with HLA-A2 and pp65 complementary DNA
(Table 2) [16].
T cells specific for influenza A are not present at high
frequencies within synovial fluid
We used a tetramer of HLA-A2 complexed with the
GILGFVFTL epitope from influenza A matrix protein to
stain paired samples of peripheral blood and synovial fluid
from six HLA-A2 patients, four of whom had RA, one of
whom had osteoarthritis and one of whom had reactive
http://arthritis-research.com/content/2/2/154
Figure 3
Frequency of IFN-g secreting antigen-specific T cells detected using an
ELISpot assay. ELISpot assays to detect IFN-g secreted by T cells
following short-term incubation with (a) the GLCTLVAML peptide or
(b) the RAKFKQLL peptide were performed on paired samples of
peripheral blood mononuclear cells (PBMCs) and synovial fluid
mononuclear cells (SFMCs). The number of spots detected per 106
mononuclear cells is shown.
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(a) (b)arthritis. Influenza-specific CD8+ T cells were unde-
tectable in both PBMC and SFMC preparations in four
donors. The frequencies of the influenza-specific CD8+
T cells in the other two donors were very low (<0.2%) in
peripheral blood and showed no enrichment within syn-
ovial fluid.
Phenotype of Epstein–Barr virus-specific T lymphocytes
within peripheral blood and synovial fluid
We analyzed expression of cell surface markers of activa-
tion and differentiation by EBV antigen-specific cells in
paired samples of peripheral blood and synovial fluid in
donor RhA7 (Figs 4 and 5). CD69 and HLA-DR are often
upregulated by activated CD8+ T cells; these molecules
were found to be expressed at higher levels on RAK-
FKQLL-specific T cells within synovial fluid than in those
found in peripheral blood (Fig. 4). Coexpression of CD69
and HLA-DR represents an unusual phenotype, but one
that has been described previously within the joint [22].
CD38 expression has also been used to identify activated
cells; this molecule was expressed on 56% of RAK-
FKQLL-specific T cells within the joint, compared with on
15% within the periphery (Fig. 5a).
L-selectin (CD62L) is downregulated after antigen stimu-
lation, with expression often being regained in the stable
memory state [23]. This molecule was expressed on only
5% of the RAKFKQLL-specific synovial fluid lymphocytes,
compared with on 23% of the cells within peripheral blood
(Fig. 5b).
CD45RA was not expressed at high levels by significant
numbers of RAKFKQLL-specific cells within synovial fluid,
but was expressed by 25% of those within peripheral
blood (Fig. 5c). The vast majority of RAKFKQLL-specific
cells within synovial fluid were CD45RO bright; 69% of
these antigen-specific cells within the periphery expressed
CD45RO [24] (Fig. 5d).
Expression of CD57, a glycoprotein of unknown function,
is thought to occur on CD8+ T cells in a late differentiation
compartment [25]. This molecule was expressed on 9% of
RAKFKQLL-specific T cells within peripheral blood and on
55% of these cells within synovial fluid (Fig. 5e).
CD28 is a costimulatory molecule that binds B7; down-
regulation of CD28 expression is associated with a dimin-
ished proliferative capacity and may reflect a state of
late–terminal differentiation [26]. This molecule was
expressed on 55% of RAKFKQLL-specific T cells within
peripheral blood and on 39% of T cells in synovial fluid
(Fig. 5f).
Analysis of GLCTLVAML-specific T cells within peripheral
blood and synovial fluid from two further donors, with RA
and osteoarthritis, respectively, revealed the same pattern,
with EBV-specific T cells within the synovial fluid showing
an increase in markers of activation and late differentiation
as compared with those in peripheral blood (data not
shown).
Discussion
The present study shows that virus-specific CD8+ T cells
are enriched in synovial fluid from individuals with inflam-
matory arthritis. In particular, CD8+ T cells specific for two
epitopes from EBV lytic cycle antigens (GLCTLVAML from
BMLF1 and RAKFKQLL from BZLF1) may be present at
very high frequency within the joints of EBV-seropositive
patients. In donor RhA5, staining with tetrameric
HLA–peptide complexes showed that T cells specific for
these two epitopes accounted for 17.6% of all CD8+
T cells within synovial fluid (over 106 cells in a single joint
aspirate). The findings described are not specific for RA
and we obtained similar results in a patient with psoriatic
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Table 2
Frequency of, and tumour necrosis factor secretion by,
synovial T cells specific for cytomegalovirus
TNF response (pg/ml)
HLA-A2-NLV+/
Patient CD8+ T cells (%) 104 105
RA3 0.2 3 45
RA11 2.3 21 102
RA14 0.5 10 61
RA15 13.9 60 70
Tumour necrosis factor (TNF) response was estimated by titrating the
amount of TNF released by 104 or 105 responder CD8+ synovial fluid
mononuclear cells after short-term incubation with COS cells
transfected with human leucocyte antigen (HLA)-A2 and pp65
complementary DNA, as described by Scotet et al [16].
Figure 4
Expression of CD69 and human leucocyte antigen (HLA) DR by
B8-RAKFKQLL-specific T cells in peripheral blood and synovial fluid
from patient RhA7. Samples of peripheral blood mononuclear cells
(dashed lines) and synovial fluid mononuclear cells (continuous lines)
were stained with the B8/RAKFKQLL tetramer, with anti-CD8 and with
monoclonal antibodies specific for CD69 or HLA-DR; 200 000 live
cells were analyzed, and expression of CD69 and HLA-DR by the
populations of CD8+ B8/RAKFKQLL tetramer reactive cells is shown.
FITC, fluorescein isothiocyanatehttp://arthritis-research.com/content/2/2/154
Figure 5
The phenotype of RAKFKQLL-specific T cells in peripheral blood and synovial fluid from patient RhA7. Samples of peripheral blood mononuclear
cells (PBMCs; left column) and synovial fluid mononuclear cells (SFMCs; right column) were stained with anti-CD8, the B8/RAKFKQLL tetramer
and with monocloncal antibodies specific for (a) CD38, (b) CD62L, (c) CD45RA, (d) CD45RO, (e) CD57 and (f) CD28. The percentage
frequency of CD8+ tetramer reactive cells that stain with the phenotypic markers are shown; 200000 live cells were included in the analysis.
FITC, fluorescein isothiocyanate.
f)
69% 95%
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55% 39%
e)
d)
a)
b)
c)
15% 56%
23% 5%
25% 2%arthritis (NR2) and in patients with osteoarthritis (NR3 and
NR4). We also found very large numbers of T cells spe-
cific for an epitope (NLVPMVATV) from the CMV tegu-
ment protein pp65 in one patient with RA, and clearly
detectable populations of T cells specific for this epitope
in three other patients with RA. We did not find high fre-
quencies of T cells specific for an epitope (FLRGRAYGL)
from the EBV latent protein EBNA3A or of T cells specific
for an epitope (GILGFVFTL) from the influenza A matrix
protein within SFMCs in the patients studied. Thus, the
synovial T-cell population is not simply a ‘concentrated’
pool of peripheral memory T cells. Many factors may con-
tribute to the enrichment of T cells specific for certain viral
antigens within the joint; these include preferential migra-
tion of subsets of T cells, local stimulation within the joint
and protection from apoptotic cell death within the joint.
T-cell migration to sites of inflammation is a carefully con-
trolled process [27–29] and T cells with an activated and
memory phenotype may be preferentially recruited to a site
of inflammation. The experiments described here show
that the antigen-specific T cells within PBMCs are rela-
tively more common in the CD62Llo, CD45RO+ and
CD45RA– compartments than in the CD62Lhi, CD45RO–
and CD45RA+ compartments. Thus, selection for acti-
vated/memory T cells is likely to account at least partly for
the observed enrichment of virus-specific T cells within the
joints. Current experiments are aimed at investigating the
importance of expression of integrins and chemokine
receptors by T cells in the recruitment of virus-specific
T cells into joints [27,30,31].
It is also possible that T cells are stimulated to proliferate
within the joints. Preliminary experiments (unpublished
data) suggest that a small proportion of CD8+ T cells
(usually <5%), including some EBV-specific T cells, are in
cell cycle within synovial fluid. The stimulus to proliferation
might be the relevant viral antigen itself. CMV DNA has
been detected in rheumatoid synovium [32]. B cells as
well as T cells are recruited into inflamed joints and, in
EBV-seropositive individuals, a subpopulation of these
B cells will be latently infected with EBV. One might there-
fore expect to find this virus within inflamed joints.
Although some early studies [33] found no evidence of
EBV infection within joints, other reports [34,35]
described detection of EBV DNA within the joints of
patients with RA and one study [36] described the use of
in situ hybridization to detect EBV-encoded small RNA1
and LMP1 transcripts in synovial lining cells from RA
patients. Furthermore Koide et al [37] derived a fibro-
blastoid cell line that expressed EBV proteins from the
synovium of a patient with RA. Very recently, Edinger et al
[38] reported detection of EBV DNA within synovia from
10 out of 11 patients with RA. That study also provides
evidence of transcription of EBV EBER1 and BZLF1 in
samples of synovia from patients with RA and osteoarthri-
tis. Thus, expression of BZLF1 within the joint may be
stimulating T cells specific for the HLA-B8 restricted RAK-
FKQLL epitope from BZLF1. Transcription of BMLF1 has,
however, not been detected within synovial tissue, sug-
gesting that alternative mechanisms may be responsible
for driving the proliferation of CD8+ T cells specific for the
HLA-A2 restricted epitope (GLCTLVAML) from BMLF1.
One possible alternative is that antigen-presenting cells
such as dendritic cells may take up EBV antigens and
subsequently be recruited to joints where they present
epitopes from the EBV antigens by ‘cross-presentation’
[39]. A second possibility is that the virus-specific T cells
are being stimulated by cross-reactive self-antigens
expressed within the joint. In favour of this is the fact that a
subpopulation of T cells specific for the HLA-B8 restricted
RAKFKQLL peptide epitope is able to cross-react with a
self peptide from a serine–threonine kinase [40].
Relative resistance to apoptotic cell death is a further the-
oretical factor that could influence the frequency of the
virus-specific T cells within the joint. Although there is evi-
dence that T cells within the joint are protected from apop-
tosis by type 1 IFN [41] there is no obvious reason to
believe that the T cells specific for the RAKFKQLL and
GLCTLVAML epitopes should survive more efficiently than
other CD8+ T cells.
The results of the ELISpot assays for IFN-g release after
incubation of SFMCs with peptide epitopes from EBV
and of the assays for TNF-a release after incubation of
SFMCs with COS cells transfected with HLA-A2 and
CMV pp65 suggest that the T cells within the synovial
fluid retain their capacity to secrete proinflammatory
cytokines. Within the joint, the secretion of such
cytokines could lead to activation of synoviocytes and
hence to the maintenance of inflammation [42]. Cell–cell
contact between the activated virus-specific T cells
within the joint and the synoviocyte population is a
second mechanism whereby the virus-specific T cells
might interact with the indigenous cells within the joint
and contribute to the pathogenesis of inflammatory joint
disease [43].
Importantly, these experiments show that large numbers of
T cells within the joint are specific for epitopes from
certain viral proteins. Many previous studies analyzed
T-cell receptor use of T cells within the joint and found evi-
dence of clonality, and concluded that the T cells are
being driven by a specific self-antigen. Paliard et al [44]
found that clonality was particularly marked within Vb14+
T cells within synovial fluid and that Vb14+ T cells were
not well represented within peripheral blood of patients
with RA. Those authors suggested that a superantigen
might have caused activation of Vb14+ T cells, with
recruitment of selected Vb14+ T cell clones into the joint
followed by deletion of Vb14+ T cells in the periphery. 
Arthritis Research    Vol 2 No 2 Tan et alIt will be interesting to analyze Vb usage of our HLA–viral
peptide tetramer-reactive CD8+ T cells. From the work we
have described, it seems likely that at least some of the
clonally expanded populations of CD8+ T cells found in
synovial fluid are specific for viral antigens. The reasons
for the presence of large numbers of synovial T cells spe-
cific for certain viral epitopes and not others remain
unclear, and the role that these virus-specific ‘bystander’
T cells may play in the maintenance of inflammation needs
further investigation.
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